218 related articles for article (PubMed ID: 11787580)
1. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Aug; 50(34):733-5. PubMed ID: 11787580
[TBL] [Abstract][Full Text] [Related]
2. From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
JAMA; 2001 Sep; 286(12):1445-6. PubMed ID: 11596606
[No Abstract] [Full Text] [Related]
3. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
[TBL] [Abstract][Full Text] [Related]
4. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.
;
MMWR Morb Mortal Wkly Rep; 2003 Aug; 52(31):735-9. PubMed ID: 12904741
[TBL] [Abstract][Full Text] [Related]
5. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Apr; 50(15):289-91. PubMed ID: 11330495
[TBL] [Abstract][Full Text] [Related]
6. From the Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
JAMA; 2002 Dec; 288(23):2967. PubMed ID: 12492097
[No Abstract] [Full Text] [Related]
7. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
McElroy PD; Ijaz K; Lambert LA; Jereb JA; Iademarco MF; Castro KG; Navin TR
Clin Infect Dis; 2005 Oct; 41(8):1125-33. PubMed ID: 16163632
[TBL] [Abstract][Full Text] [Related]
8. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection.
Ijaz K; Jereb JA; Lambert LA; Bower WA; Spradling PR; McElroy PD; Iademarco MF; Navin TR; Castro KG
Clin Infect Dis; 2006 Feb; 42(3):346-55. PubMed ID: 16392079
[TBL] [Abstract][Full Text] [Related]
9. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
Gordin FM; Cohn DL; Matts JP; Chaisson RE; O'Brien RJ; ; ;
Clin Infect Dis; 2004 Aug; 39(4):561-5. PubMed ID: 15356822
[TBL] [Abstract][Full Text] [Related]
10. Tuberculosis prevention in Mexican immigrants: limitations of short-course therapy.
Kandula NR; Dworkin MS; Carroll MR; Lauderdale DS
Am J Prev Med; 2004 Feb; 26(2):163-6. PubMed ID: 14751331
[TBL] [Abstract][Full Text] [Related]
11. Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis.
Potolidis E; Mantadakis E; Zeniodi MH; Samonis G
Scand J Infect Dis; 2005; 37(2):155-7. PubMed ID: 15773037
[TBL] [Abstract][Full Text] [Related]
12. Rifampin and pyrazinamide for treatment of latent tuberculosis infection.
Cook PP
Clin Infect Dis; 2006 Mar; 42(6):892; author reply 892-3. PubMed ID: 16477576
[No Abstract] [Full Text] [Related]
13. From the Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
JAMA; 2001 May 23-30; 285(20):2572-3. PubMed ID: 11396466
[No Abstract] [Full Text] [Related]
14. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
[TBL] [Abstract][Full Text] [Related]
15. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
[TBL] [Abstract][Full Text] [Related]
16. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.
Cook PP; Maldonado RA; Yarnell CT; Holbert D
Clin Infect Dis; 2006 Aug; 43(3):271-5. PubMed ID: 16804838
[TBL] [Abstract][Full Text] [Related]
17. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
McNeill L; Allen M; Estrada C; Cook P
Chest; 2003 Jan; 123(1):102-6. PubMed ID: 12527609
[TBL] [Abstract][Full Text] [Related]
18. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
Jasmer RM; Daley CL
Am J Respir Crit Care Med; 2003 Mar; 167(6):809-10. PubMed ID: 12623855
[No Abstract] [Full Text] [Related]
19. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.
Kunimoto D; Warman A; Beckon A; Doering D; Melenka L
Clin Infect Dis; 2003 Jun; 36(12):e158-61. PubMed ID: 12802781
[TBL] [Abstract][Full Text] [Related]
20. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
